ReNeuron Group (RENE); announces sustained and further improvement in first cohort of Phase 2a study

Published on 26-04-2019 07:48:26
Author Sparks Team

ReNeuron Group has announced that all three subjects in the first cohort of the Phase 2a element of human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), have demonstrated a sustained and further improvement in vision compared with their pre-treatment baseline.

Recently, ReNeuron’s study exhibited a mean improvement from the baseline in visual acuity of more than +23 letters in the treated eyes, compared to no improvement in the untreated control eyes.

Olav Hellebø, ReNeuron’s CEO, said: “The extent of vision improvement observed in this patient cohort demonstrates the potential for our hRPC cell therapy candidate to make an enormous difference in the lives of patients with RP. Treatment has already begun in the next cohort of patients, who have a greater baseline level of visual acuity than those treated so far.”

Share this with friends and colleagues